Streetbeat News

Products Services

MRK

Merck announced that its Phase 3 KEYNOTE-811 trial of Keytruda met its dual primary endpoint of overall survival as a first-line treatment of HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma. This marks a significant advancement in the treatment of this cancer type.

Portfolio Pulse from Benzinga Newsdesk

May 01, 2024 | 11:17 am

BCDA

BioCardia announced results from its open label roll-in cohort study for patients with chronic myocardial ischemia and refractory angina, showing an average increase in exercise tolerance of 107 seconds and an average reduction in angina episodes of 82% at the six-month follow-up.

Portfolio Pulse from Benzinga Newsdesk

May 01, 2024 | 11:15 am

ULTA

Ulta Beauty announced a strategic mission aimed at enhancing well-being for women and teens, signaling a potential shift in its business focus towards health and wellness.

Portfolio Pulse from Benzinga Newsdesk

May 01, 2024 | 11:15 am

NTRA

Natera, Inc. has announced the launch of a new cell-free DNA (cfDNA)-based test for determining fetal Rhesus D (RhD) status, expanding its portfolio of non-invasive prenatal tests.

Portfolio Pulse from Benzinga Newsdesk

May 01, 2024 | 11:15 am

VTRS

Viatris has introduced Unmind, a mental health platform, as a component of its global wellbeing initiative, Elevate. This move underscores the company's commitment to enhancing the mental health and overall wellbeing of its workforce.

Portfolio Pulse from Benzinga Newsdesk

May 01, 2024 | 11:14 am

CMRX

Chimerix announced expectations for interim overall survival data for Dordaviprone in 2025 and final data in 2026. Dordaviprone is a novel oral molecule targeting DRD2 and ClpP for potential therapeutic applications.

Portfolio Pulse from Benzinga Newsdesk

May 01, 2024 | 11:13 am

MCD

McDonald's Corp. (NYSE:MCD) is testing a larger burger in select global markets as part of its growth strategy focusing on the core menu to boost sales. This initiative follows a reported 4.6% year-on-year increase in first-quarter sales to $6.17 billion, surpassing analyst estimates. The move aims to address a slowdown in demand, especially in the U.S., and compete with rising menu prices in California due to minimum wage increases.

Portfolio Pulse from Benzinga Neuro

May 01, 2024 | 11:12 am

NBIX

Neurocrine Biosciences has reaffirmed its fiscal year 2024 net product sales forecast for INGREZZA, projecting sales to be in the range of $2.10 billion to $2.20 billion.

Portfolio Pulse from Benzinga Newsdesk

May 01, 2024 | 11:10 am

DGX

Quest Diagnostics has announced a collaboration aimed at accelerating the adoption of digital and AI pathology innovations to enhance the quality, speed, and efficiency of diagnosing cancer and other diseases.

Portfolio Pulse from Benzinga Newsdesk

May 01, 2024 | 10:58 am

PFE

Pfizer plans to sell its Covid and migraine drugs directly to consumers, as reported by the Financial Times. This move could potentially reshape the pharmaceutical distribution landscape and impact how consumers access these medications.

Portfolio Pulse from Benzinga Newsdesk

May 01, 2024 | 10:45 am